Onychomycosis. Agents of choice.
The management of onychomycosis has changed considerably in the past few years. The main trends have been improvement in the choice of evidence and cover of infections other than dermatophytosis, shortening of periods of oral therapy, and introduction of topical agents designed to treat nail disease. At present there have been almost no comparative studies of these different approaches, and choice is therefore largely based on enlightened guesswork coupled with personal experience. It is hoped that within the next few years such studies will be carried out to allow dermatologists to make an accurate choice based on appropriate scientific data.
Hay
R J
RJ
St. John's Institute of Dermatology, Guy's Hospital, London, United Kingdom.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000935:Antifungal Agents / Q000627:therapeutic use*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D015725:Fluconazole / Q000627:therapeutic use; D005533:Foot Dermatoses; D006118:Griseofulvin / Q000627:therapeutic use; D006229:Hand Dermatoses; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D006118:Griseofulvin; D015725:Fluconazole; D000077291:Terbinafine; D007654:Ketoconazole